Recro Reports Financial Results for the Year Ended 2019

Recro Completes Separation of Baudax Bio and Is Now a Pure Play CDMO Business
Company Sets Annual Revenue Record; 2019 Revenues of $99.2 MillionCompany to Host Conference Call Today at 8:00 AM ETMALVERN, Pa., March 04, 2020 (GLOBE NEWSWIRE) — Recro Pharma, Inc. (Nasdaq:REPH), a high-performing, revenue generating contract development and manufacturing organization (CDMO), today reported financial results for the year ended December 31, 2019.“The CDMO business has continued to deliver record results in 2019, generating $99.2 million in full year revenues, a 28% increase over the comparable twelve-month period in 2018,” said Gerri Henwood, President and Chief Executive Officer of Recro.  “Looking ahead to 2020, we look forward to continuing to meet the needs of our commercial customers as well as filling our development pipeline to diversify our portfolio.”Recent HighlightsCompleted Separation of Baudax Bio, Becoming a Pure Play CDMO.  Proactively executing on its strategy to drive growth and build on the strength and commercial success of its CDMO business, Recro completed the spin out of its Acute Care business, Baudax Bio, in November 2019. The board of directors approved the separation of Baudax Bio and Recro and declared a special dividend distribution of one share of Baudax Bio common stock for every two and one half shares of Recro common stock held. Baudax Bio common stock began trading in November 2019 under the symbol “BXRX” on the Nasdaq Capital Market.
 
2019 Set an Annual Revenue Record.  Recro continued its strong performance, generating revenues of $99.2 million.  For the full year 2019, operating income from continuing operations, operating income, as adjusted*, and EBITDA, as adjusted* were $23.6 million, $32.3 million and $49.0 million, respectively.Year End 2019 Financial ResultsAs of December 31, 2019, Recro had cash and cash equivalents of approximately $19.1 million.Because the Acute Care business is presented as a discontinued operation as of December 31, 2019, the Acute Care businesses’ results are excluded from the Company’s continuing operations for all periods presented.Revenues were $99.2 million and $77.3 million for the years ended December 31, 2019 and 2018, respectively. The increase of $21.9 million in 2019 revenue versus 2018 revenue was due to increased royalties recognized from one of the Company’s commercial partners and an increase in product sales to various commercial partners.Cost of sales were $51.0 million and $43.2 million for the years ended December 31, 2019 and 2018, respectively, which increased primarily due to product mix and expanded service and development capabilities as well as growth in manufacturing demand.There were no research and development expenses in the year ended December 31, 2019. Research and development expenses were $4.4 million for the year ended December 31, 2018. The decrease of $4.4 million in 2019 primarily resulted from the inclusion of such costs in cost of sales in 2019 rather than research and development due to the change of focus of the personnel to revenue generating activities.Selling, general and administrative expenses were $19.9 million and $14.4 million for the years ended December 31, 2019 and 2018, respectively. The increase of $5.5 million was primarily due to higher public company costs, including corporate initiatives, which increased by $4.1 million to $16.3 million for the year ended December 31, 2019 compared to $12.2 million for the year ended December 31, 2018. The remaining $1.4 million increase was driven by higher business development costs, as the Company expanded its sales team in various geographies in anticipation of business growth from new formulation and development capabilities.Amortization of intangible assets expense was $2.6 million for each of the years ended December 31, 2019 and 2018, respectively and relates to the amortization of Recro’s royalties and contract manufacturing relationships intangible asset over its estimated useful life.Interest expense, net, was $19.0 million and $8.1 million during the years ended December 31, 2019 and 2018, respectively. The increase in interest expense, net, was due to the higher principal balance on the Company’s Athyrium senior secured term loan and amortization of the related financing costs.The Company records a full valuation allowance against its deferred tax assets therefore, there was no income tax benefit for the year ended December 31, 2019. Income tax expense for the year ended December 31, 2018 was $17.4 million primarily due to recording of a one-time, non-cash income tax valuation allowance against its domestic deferred tax assets.For the year ended December 31, 2019, Recro reported net income from continuing operations of $4.6 million, or $0.20 net income per diluted share and net loss of $13.1 million, or $0.64 net loss per diluted share for the year ended December 31, 2018. Including the impact of discontinued operations, the Company reported a net loss of $18.6 million, or $0.79 net loss per diluted share, for the year ended December 31, 2019 compared to a net loss of $79.7 million, or $3.90 net loss per diluted share, for the comparable period in 2018.Financial GuidanceFor 2020, the Company expects revenue to be in the range of $97-$100 million, depending upon  market dynamics, contracts, timing of customer order patterns, accuracy of our customer’s product market estimations, new market entrants, and success and timing related to business development activities. The Company expects its Operating Income to be in the range of $21.3-$25.3 million and Operating income, as adjusted* to be in the range of $27.3-$30.3 million. The Company also expects its EBITDA, as adjusted* to be in the range of $47-50 million.*Operating Income, as adjusted and EBITDA, as adjusted are non-GAAP financial measures (See reconciliation of non-GAAP financial measures in this release).Conference Call and WebcastRecro management will be hosting a conference call and webcast today beginning at 8:00 a.m. ET. To access the conference call, please dial (844) 243-4691 (local) or (225) 283-0379 (international) at least 10 minutes prior to the start time and refer to conference ID 4297426. A webcast will be available in the “Investors” section of the Company’s website, www.recrogainesville.com. A live audio webcast of the call will be available under “Events” in the “Investors” section of the Company’s website, https://recrogainesville.com. An archived webcast will be available on the Company’s website approximately two hours after the event and will be available for 30 days.Non-GAAP Financial MeasuresIn addition to the United States generally accepted accounting principles (GAAP) results, this earnings release includes Operating Income, as adjusted and EBITDA, as adjusted, non-GAAP financial measures. Management uses includes Operating Income, as adjusted and EBITDA, as adjusted in its evaluation of the Company’s liquidity and trends between fiscal periods. Management believes that this non-GAAP financial information reflects an additional way of viewing aspects of our business that, when viewed with our GAAP results, provides a more complete understanding of factors and trends affecting our business.The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. In addition, these measures may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes. Please see the section of this press release titled “Reconciliation of includes Operating Income, as adjusted and EBITDA, as adjusted” for a reconciliation of includes Operating Income, as adjusted and EBITDA, as adjusted to their most directly comparable GAAP financial measures.About RecroRecro is a revenue-generating contract development and manufacturing, or CDMO, business, located in Gainesville, GA. The Company leverages its formulation expertise to develop and manufacture pharmaceutical products using its proprietary delivery technologies and other manufacturing services for commercial and development-stage partners who commercialize or plan to commercialize these products. These collaborations can result in revenue streams including royalties, profit sharing, research and development and manufacturing fees, which support continued operations for the business. For more information please visit www.recrogainesville.com.Cautionary Statement Regarding Forward Looking StatementsThis press release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Recro’s expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “may,” “upcoming,” “plan,” “target,” “intend” and “expect” and similar expressions, as they relate to Recro or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information available to Recro as of the date of this press release and are subject to a number of risks, uncertainties, and other factors that could cause Recro’s performance to differ materially from those expressed in, or implied by, these forward-looking statements. The following are some of the factors that could cause our actual results to differ materially from those expressed in or underlying our forward-looking statements: customers’ changing inventory requirements and manufacturing plans; customers and prospective customers decisions to move forward with our manufacturing services; average profitability, or mix, of the products we manufacture; or customers facing increasing or new competition.  This list of important factors is not all inclusive. Recro assumes no obligation to update any such forward-looking statements. Factors that could cause Recro’s actual performance to materially differ from those expressed in the forward-looking statements set forth in this press release include, without limitation, the risks and uncertainties included in Recro’s filings with the Securities and Exchange Commission at www.sec.gov.Contact:Investor Relations Contact:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
[email protected]
[email protected]
Recro
Ryan D. Lake
(484) 395-2436
[email protected]
Media Contact:
Argot Partners
David Rosen
(212) 600-1902
[email protected]

 



Bay Street News

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search